RNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and severe acute respiratory syndrome coronavirus ...

CoV-2, the virus behind Covid-19, is less likely to cause long Covid -- a condition that affects at least 65 million people ...

THE Covid‐19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has represented a paramount ...

An executive order signed on May 5, 2025, weaponizes the false claim that the virus that causes COVID-19 was manufactured in ...

Cardiovascular issues are common, and now some experts term severe COVID an independent coronary artery disease risk factor ...

Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m ...

Analysis of excess deaths in 2021 reveals significant undercounting of COVID-19 fatalities, with some states reporting 44 times fewer deaths.

Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few months.

Despite widespread vaccine availability and improved treatment strategies, certain patients with SARDs remain highly vulnerable to severe COVID-19 outcomes.

From a software engineering standpoint, Bacon said the two fundamental improvements OpenSAFELY brings to medical analytics ...

Phase 3 results show the investigational drug norucholic acid is superior to placebo in halting disease progression.